Compare BHVN & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | PFLT |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 899.9M |
| IPO Year | 2017 | N/A |
| Metric | BHVN | PFLT |
|---|---|---|
| Price | $10.76 | $9.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $30.36 | $10.75 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 03-02-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 13.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $261,427,000.00 |
| Revenue This Year | N/A | $11.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.01 |
| Revenue Growth | N/A | ★ 40.28 |
| 52 Week Low | $7.48 | $8.40 |
| 52 Week High | $44.28 | $11.50 |
| Indicator | BHVN | PFLT |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 47.95 |
| Support Level | $10.61 | $9.27 |
| Resistance Level | $12.90 | $9.53 |
| Average True Range (ATR) | 0.80 | 0.15 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 17.66 | 41.42 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.